Cardiomyopathies

Cardiomyopathies: How Cardiac MRI Helps Diagnose and Monitor Heart Muscle Disease

What Is Cardiomyopathy?

Cardiomyopathies are among the most common causes of heart failure, serious arrhythmias, and sudden cardiac death, including in otherwise healthy adults and young athletes. They affect people of all ages and backgrounds, and many forms have a genetic component, meaning family members of affected individuals may also be at risk.

Accurate diagnosis is essential because the different types of cardiomyopathy require very different approaches to treatment, monitoring, and risk management. Cardiac MRI has become one of the most important tools available for identifying, characterizing, and tracking these conditions with a level of detail that other imaging modalities cannot always provide.

Types of Cardiomyopathy

There are several distinct types of cardiomyopathy, each with its own pattern of disease, underlying causes, and clinical implications.

Hypertrophic Cardiomyopathy (HCM) is characterized by abnormal thickening of the heart muscle, most commonly affecting the left ventricle. It is largely genetic in origin and is one of the most common causes of sudden cardiac death in young people, including competitive athletes. Many individuals with HCM have no symptoms for years, while others experience shortness of breath, chest pain, or palpitations. In some cases, the thickened muscle obstructs blood flow out of the heart.

Dilated Cardiomyopathy (DCM) is the most common form of cardiomyopathy. The left ventricle becomes enlarged and weakened, reducing the heart’s pumping efficiency. Causes include genetic mutations, prior viral infections of the heart, chronic alcohol use, certain chemotherapy agents, and in many cases, no identifiable cause is found. Symptoms typically include fatigue, shortness of breath, and signs of heart failure.

Restrictive Cardiomyopathy is less common but among the more serious forms. The heart muscle becomes abnormally stiff, impairing the ventricles’ ability to fill with blood between beats. It is often associated with infiltrative diseases — conditions in which abnormal substances accumulate within the heart muscle. Cardiac amyloidosis, in which misfolded proteins deposit in the myocardium, and hemochromatosis, involving iron overload, are two important examples. Cardiac sarcoidosis, inflammatory granulomas in the heart, is another.

Arrhythmogenic Cardiomyopathy (ACM), also known as ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy), involves the progressive replacement of heart muscle — primarily in the right ventricle — with fatty or fibrous tissue. This structural change disrupts the heart’s electrical system and creates a substrate for life-threatening arrhythmias. ACM is hereditary in most cases and is an important cause of sudden cardiac death in young people.

Takotsubo Cardiomyopathy, often called stress cardiomyopathy, involves a sudden, temporary weakening of the left ventricle, typically triggered by intense physical or emotional stress. The condition mimics a heart attack in its presentation but is not caused by blocked coronary arteries. In most cases, it resolves fully with supportive care, though careful imaging is required to confirm the diagnosis and rule out other causes.

How Cardiac MRI Is Used to Diagnose and Monitor Cardiomyopathies

Cardiac MRI has become the gold standard imaging modality for evaluating cardiomyopathies because it combines precise functional assessment with unmatched tissue characterization — all without radiation exposure. It is not limited by a patient’s body habitus or acoustic windows the way echocardiography can be, and it can reveal abnormalities within the heart muscle itself that are invisible to other imaging methods.

Several specialized MRI techniques are used depending on what is being evaluated:

Cine MRI produces dynamic images of the heart throughout the cardiac cycle, enabling precise measurement of ventricular chamber size, wall thickness, wall motion, and ejection fraction. This is the primary tool for diagnosing and quantifying DCM, as well as assessing functional impairment in any cardiomyopathy.

Late Gadolinium Enhancement (LGE) is one of the most clinically valuable techniques in cardiomyopathy imaging. After intravenous gadolinium contrast is administered, damaged or fibrotic myocardial tissue retains the contrast agent longer than healthy tissue, appearing bright on imaging. The pattern and distribution of LGE is highly specific: in HCM, fibrosis appears in the hypertrophied segments and is directly associated with arrhythmia risk and sudden death; in DCM, a mid-wall or patchy pattern of LGE helps distinguish non-ischemic from ischemic disease; in ACM, LGE identifies fibrofatty infiltration in the right ventricular wall; in Takotsubo, the absence of LGE helps confirm the diagnosis and rule out myocardial infarction.

T1 and T2 Mapping are quantitative techniques that measure tissue relaxation properties, providing a sensitive and objective assessment of myocardial composition. T1 mapping is particularly valuable in diagnosing infiltrative cardiomyopathies: cardiac amyloidosis produces a characteristic pattern of elevated T1 values and diffuse LGE that is highly diagnostic; iron overload in hemochromatosis causes a reduction in T1 values reflecting iron deposition. T2 mapping detects myocardial edema and inflammation, and is useful in distinguishing acute from chronic disease and in evaluating sarcoidosis.

T2-weighted imaging identifies areas of active myocardial inflammation or edema, supporting the diagnosis of myocarditis — which can mimic or overlap with cardiomyopathy — and helping assess disease acuity.

Beyond initial diagnosis, cardiac MRI plays an important role in long-term disease monitoring and risk stratification. Serial MRI examinations track changes in ventricular size, function, and fibrosis burden over time, informing decisions about implantable cardioverter-defibrillators (ICDs) for patients at risk of sudden cardiac death, optimizing heart failure medications, and evaluating candidacy for advanced therapies such as cardiac transplantation. In HCM specifically, the extent of LGE-detected fibrosis has emerged as an important predictor of adverse outcomes and guides device therapy recommendations.

What Patients Can Expect

A cardiac MRI typically takes 45 to 75 minutes. Most cardiac MRI exams require an intravenous contrast agent (gadolinium) to evaluate tissue characteristics fully. ECG electrodes are placed on the chest to synchronize image acquisition with the heartbeat, and patients are asked to hold their breath briefly during certain sequences. The exam is non-invasive and involves no radiation.

Patients with kidney disease will be screened before contrast administration, as gadolinium is cleared by the kidneys. For complete preparation information, please visit GWIC’s [MRI preparation page].

Greater Waterbury Imaging Center provides cardiac MRI services with protocols tailored to the evaluation of cardiomyopathies, including LGE, T1/T2 mapping, and cine imaging. To refer a patient or discuss imaging options, please contact us at 203.573.7674 or visit our Physician Tools page.

References

1. Arbelo, E., Protonotarios, A., Gimeno, J. R., et al. (2023). 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal, 44(37), 3503–3626. https://doi.org/10.1093/eurheartj/ehad194
2. Messroghli, D. R., Moon, J. C., Ferreira, V. M., et al. (2017). Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume. Journal of Cardiovascular Magnetic Resonance, 19(1), 75. https://doi.org/10.1186/s12968-017-0389-8
3. Kramer, C. M., Barkhausen, J., Bucciarelli-Ducci, C., et al. (2020). Standardized cardiovascular magnetic resonance imaging protocols: 2020 update. Journal of Cardiovascular Magnetic Resonance, 22(1), 17. https://doi.org/10.1186/s12968-020-00607-1
4. Ommen, S. R., Mital, S., Burke, M. A., et al. (2020). 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 76(25), e159–e240. https://doi.org/10.1016/j.jacc.2020.08.045

Additional Information:

• Cardiac MRI
• Coronary Artery Disease